Objectives: New Trend For Hair loss
IMCAS 2020

We will present the last trends and development in traitment of alopecia.
1/ Patelet rich plasma PRP in alopecia with clinical data:
Clinical revealance og RegenPRP in AGA
Dr. GHINI case serie
NYU Prof. Jerry Shapiro clinical study

2/PRP in the future
PRP for hairloss post chemiatherapy
Dr. Anthony Rossi ongoing clinical study
Cellular matrix; combination of PRP and HA for hair loss
3/AQ SKIN - Growth factor drived from modified human fibroblast in traitment of alopecia
4/ Synthetic hair implant – A breakthrough in hair implants. Nylon fiber wi

Introduction: .

Materials / method: .

Results: .

Conclusion: .

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: SUMMARY LECTURE DR. SERGIO VAÑÓ
IMCAS CONGRESS JANUARY 2020

MY BEST THERAPIES FOR ANDROGENETIC ALOPECIA

During the lecture we will discuss 3 treatments for androgenetic alopecia:
a) Oral dutasteride: a 5 alpha reductase inhibitor that can be used off label in male and female androgenetic alopecia. It represents one of the most effective therapies for male androgenetic alopecia. We will present the results of our experience with the use of oral dutasteride in male patients, using doses between 0.25 and 0.5 mg daily.

Introduction: b) Oral minoxidil: we will review the usefulness of oral minoxidil for male and female androgenetic alopecia. In our experience, oral minoxidil is one of the most interesting therapies for female androgenetic alopecia, using doses between 0.5-1 mg daily.
c) Injections of dutasteride: we will present our experience and scientific evidence of an emergent treatment modality: mesotherapy with dutasteride.

Materials / method: Dr. Sergio Vañó Galván, MD, PhD
Dermatologist, Head of Trichology Unit. Clinical research coordinator. Ramon y Cajal Hospital, Madrid, Spain.
Coordinator of the Spanish Group of Trichology.
Director of Trichology Unit of the Grupo Pedro Jaen Clinic, Madrid, Spain.
Professor, University of Alcala, Madrid
Email: drsergiovano@gmail.com

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Learn about the background of hair growth therapies in general and new treatment modalities in particular

Introduction: Androgentic Alopecia (AA) is a very interesting area for company to explore new therapies. An abundance of treatments come to light every year. Many of them indeed do work. However, there has to be assessed which one is clinically useful.

Materials / method: Literature and personal experiences are being presented

Results: These therapy groups will be covered: (1) oral medication (the finasteride/dutasteride case), (2) new topicals, (3) devices. All of this against the backrgoud of what we know about hair growth in general and the problem of AA in particular.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： dts mg